Quest Diagnostics (DGX) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Jan 21, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Michael J. Deppe, Svp, Corp. Controller & Cao sold 6,261 shares at $260.17 ($1.6M).
- Trade date
- Nov 13, 2026
- Disclosed to the SEC
- Nov 16, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All DGX insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
DGX insider transactions (Form 4)
Open-market purchases and sales. 112 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 16SEC | Michael J. DeppeSvp, Corp. Controller & Cao | Sell Plan | 6,26135,203 held (−15%) | $260.17 | $1.6M | -0.4% | — |
| Nov 16SEC | Michael J. DeppeSvp, Corp. Controller & Cao | Sell Plan | 5,51535,203 held (−14%) | $260.17 | $1.4M | -0.4% | — |
| Nov 12SEC | Patrick PlewmanSvp For Diagnostic Services | Sell Plan | 6,79315,334 held (−31%) | $257.34 | $1.7M | +0.7% | — |
| Nov 12SEC | Patrick PlewmanSvp For Diagnostic Services | Sell Plan | 4,27415,334 held (−22%) | $257.34 | $1.1M | +0.7% | — |
| Nov 12SEC | Patrick PlewmanSvp For Diagnostic Services | Sell Plan | 65014,684 held (−4%) | $257.34 | $167K | +0.7% | — |
| Nov 5SEC | Catherine T. DohertyPresident | Sell Plan | 5,99084,246 held (−7%) | $246.26 | $1.5M | +5.2% | — |
| Nov 5SEC | Catherine T. DohertyPresident | Sell Plan | 3,81890,236 held (−4%) | $245.45 | $937K | +5.5% | — |
| Nov 5SEC | Catherine T. DohertyPresident | Sell Plan | 3,00477,733 held (−4%) | $249.40 | $749K | +3.9% | — |
| Nov 5SEC | Catherine T. DohertyPresident | Sell Plan | 2,90771,949 held (−4%) | $251.24 | $730K | +3.1% | — |
| Nov 5SEC | Catherine T. DohertyPresident | Sell Plan | 2,87774,856 held (−4%) | $250.49 | $721K | +3.4% | — |
| Nov 5SEC | Catherine T. DohertyPresident | Sell Plan | 2,35880,737 held (−3%) | $248.38 | $586K | +4.3% | — |
| Nov 5SEC | Catherine T. DohertyPresident | Sell Plan | 1,15183,095 held (−1%) | $246.98 | $284K | +4.9% | — |
| Oct 28SEC | Gary M. PfeifferDirector | Sell Plan | 1,20329,802 held (−4%) | $243.00 | $292K | +6.6% | — |
| Sep 3SEC | J. E. DavisCEO, President | Sell Plan | 10,000122,423 held (−8%) | $242.72 | $2.4M | +6.7% | — |
| Aug 31SEC | Michael E. PrevoznikGeneral Counsel | Sell Plan | 16,01044,224 held (−27%) | $242.88 | $3.9M | +6.7% | — |
| Aug 31SEC | Michael E. PrevoznikGeneral Counsel | Sell Plan | 6,23737,987 held (−14%) | $243.63 | $1.5M | +6.3% | — |
| Aug 31SEC | Michael E. PrevoznikGeneral Counsel | Sell Plan | 43037,557 held (−1%) | $244.51 | $105K | +5.9% | — |
| Jul 29SEC | Mark E. DelaneySvp & Chief Commercial Officer | Sell Plan | 1,60010,335 held (−13%) | $235.18 | $376K | +10.2% | — |
| Jun 8SEC | Karthik KuppusamySvp, Clinical Solutions | Sell Plan | 8,14713,510 held (−38%) | $200.00 | $1.6M | +29.5% | — |
| Jun 2SEC | J. E. DavisCEO, President | Sell Plan | 10,000132,423 held (−7%) | $194.14 | $1.9M | +33.4% | — |
| Mar 6SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 5,55867,122 held (−8%) | $206.21 | $1.1M | +25.6% | — |
| Mar 6SEC | Michael E. PrevoznikGeneral Counsel | Sell Plan | 3,87837,557 held (−9%) | $206.21 | $800K | +25.6% | — |
| Mar 6SEC | Patrick PlewmanSvp For Diagnostic Services | Sell Plan | 2,85515,198 held (−16%) | $206.21 | $589K | +25.6% | — |
| Mar 6SEC | Karthik KuppusamySvp, Clinical Solutions | Sell | 2,62813,441 held (−16%) | $204.86 | $538K | +26.5% | — |
| Mar 4SEC | J. E. DavisCEO, President | Sell Plan | 10,000117,185 held (−8%) | $212.52 | $2.1M | +21.9% | — |
| Mar 4SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 63267,122 held (−1%) | $207.73 | $131K | +24.7% | — |
| Mar 4SEC | Michael E. PrevoznikGeneral Counsel | Sell Plan | 52637,557 held (−1%) | $207.73 | $109K | +24.7% | — |
| Mar 4SEC | Patrick PlewmanSvp For Diagnostic Services | Sell Plan | 41015,198 held (−3%) | $207.73 | $85K | +24.7% | — |
| Feb 20SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 1,43368,402 held (−2%) | $204.83 | $294K | +26.5% | — |
| Feb 20SEC | Michael E. PrevoznikGeneral Counsel | Sell Plan | 1,11138,371 held (−3%) | $204.83 | $228K | +26.5% | — |
| Feb 20SEC | Patrick PlewmanSvp For Diagnostic Services | Sell Plan | 95815,838 held (−6%) | $204.83 | $196K | +26.5% | — |
| Feb 17SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 10,57383,660 held (−11%) | $205.21 | $2.2M | +26.2% | — |
| Feb 17SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 10,12273,538 held (−12%) | $206.37 | $2.1M | +25.5% | — |
| Feb 17SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 3,50070,038 held (−5%) | $207.08 | $725K | +25.1% | — |
| Feb 17SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 1,61968,419 held (−2%) | $208.21 | $337K | +24.4% | — |
| Feb 17SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 35168,068 held (−1%) | $209.10 | $73K | +23.9% | — |
| Feb 12SEC | Patrick PlewmanSvp For Diagnostic Services | Sell Plan | 5,66215,381 held (−27%) | $204.00 | $1.2M | +27.0% | — |
| Nov 28SEC | J. E. DavisCEO, President | Sell Plan | 41,004125,227 held (−25%) | $192.27 | $7.9M | +34.7% | — |
| Nov 28SEC | J. E. DavisCEO, President | Sell Plan | 9,342166,231 held (−5%) | $191.59 | $1.8M | +35.2% | — |
| Nov 28SEC | J. E. DavisCEO, President | Sell Plan | 4,747120,480 held (−4%) | $192.97 | $916K | +34.2% | — |
| Nov 28SEC | Vicky B. GreggDirector | Sell | 1,25017,037 held (−7%) | $191.76 | $240K | +35.1% | — |
| Nov 20SEC | Mark E. DelaneySvp & Chief Commercial Officer | Sell Plan | 7,9467,530 held (−51%) | $187.35 | $1.5M | +38.3% | — |
| Oct 24SEC | Gary M. PfeifferDirector | Sell | 1,48229,431 held (−5%) | $182.40 | $270K | +42.0% | — |
Similar past setups: not applicable. DGX has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with DGX in the Research Lab
DGX has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Quest Diagnostics insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $48.8M of DGX stock on the open market; P/E 27.6 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
DGX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $11.9M | 13 |
| Q3 2026 | — | 0 | $8.3M | 5 |
| Q2 2026 | — | 0 | $3.6M | 2 |
| Q1 2026 | — | 0 | $12.8M | 17 |
| Q4 2025 | — | 0 | $12.6M | 6 |
Valuation, profit and volume
Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Quest Diagnostics insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $48.8M. 40 of 43 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
DGX earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 22, 2026 | +4.6% | None | +1.2%S&P -1.7% | pending |
| Jul 23, 2026 | -0.8% | None | +8.6%S&P -1.1% | +7.3% |
| Apr 21, 2026 | -0.4% | None | +3.9%S&P +0.4% | -4.3% |
| Feb 10, 2026 | +5.7% | None | +9.4%S&P -0.3% | -4.6% |
| Jan 12, 2026 | -0.8% | None | +3.6%S&P -0.0% | +14.9% |
| Oct 21, 2025 | +6.2% | None | -4.9%S&P -0.5% | +5.6% |
| Jul 22, 2025 | -5.5% | None | +2.4%S&P +0.9% | +5.7% |
| Apr 22, 2025 | -0.9% | None | +7.2%S&P +4.2% | -1.3% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
DGX short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded DGX
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 30, 2026 | Jul 21, 2026 | +33.0% |
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | +34.1% |
Insiders at Quest Diagnostics
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| J. E. DavisCEO, President | — | $17.1M | Sep 3, 2026 | — | — |
| Catherine T. DohertyPresident | — | $12.4M | Nov 5, 2026 | — | — |
| Michael E. PrevoznikGeneral Counsel | — | $6.6M | Aug 31, 2026 | — | — |
| Patrick PlewmanSvp For Diagnostic Services | — | $5.0M | Nov 12, 2026 | — | — |
| Michael J. DeppeSvp, Corp. Controller & Cao | — | $3.1M | Nov 16, 2026 | — | — |
| Karthik KuppusamySvp, Clinical Solutions | — | $2.2M | Oct 23, 2026 | — | — |
| Mark E. DelaneySvp & Chief Commercial Officer | — | $1.9M | Nov 5, 2026 | — | — |
| Gary M. PfeifferDirector | — | $563K | Oct 28, 2026 | — | — |
| Vicky B. GreggDirector | — | $240K | Oct 23, 2026 | — | — |
| Subu RamachandranSvp, Regional Businesses | — | — | Nov 5, 2026 | — | — |
| Sam SamadCFO, President | — | — | Oct 23, 2026 | — | — |
| Timothy L. MainDirector | — | — | Oct 23, 2026 | — | — |
| Robert B. CarterDirector | — | — | Oct 23, 2026 | — | — |
| Wright Lassiter IIIDirector | — | — | Oct 23, 2026 | — | — |
| Timothy M. RingDirector | — | — | May 21, 2026 | — | — |
| Denise M. MorrisonDirector | — | — | May 21, 2026 | — | — |
| Timothy C. WentworthDirector | — | — | May 21, 2026 | — | — |
| Tracey DoiDirector | — | — | May 21, 2026 | — | — |
| Luis DiazDirector | — | — | May 21, 2026 | — | — |
Board links: companies that share insiders with DGX
Directors and executives who filed Form 4s for DGX and another company in the last 12 months.
- BDXBecton Dickinson Timothy M. Ring Director here · Director at BDX · latest filing May 21, 2026
- FTVFortive Wright Lassiter III Director here · Director at FTV · latest filing Oct 23, 2026
- METMetLife Denise M. Morrison Director here · Director at MET · latest filing May 21, 2026
- PNRPentair Tracey Doi Director here · Director at PNR · latest filing May 21, 2026
- VVisa Denise M. Morrison Director here · Director at V · latest filing May 21, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
DGX stock: common questions
Are Quest Diagnostics insiders buying DGX stock?
No. No Quest Diagnostics insider reported an open-market purchase of DGX in the past 12 months.
Are Quest Diagnostics insiders selling DGX stock?
9 insiders reported sales worth $48.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is DGX's P/E ratio?
DGX trades at about 27.6 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is DGX's 52-week range?
Over the past year DGX has traded between $170.62 and $262.21. It last closed at $259.06 on Nov 19, 2026.